158 related articles for article (PubMed ID: 38651109)
1. Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps.
Cuccarini V; Savoldi F; Mardor Y; Last D; Pellegatta S; Mazzi F; Bruzzone MG; Anghileri E; Pollo B; Maddaloni L; Russo C; Bocchi E; Pinzi V; Eoli M; Aquino D
Front Neurol; 2024; 15():1374737. PubMed ID: 38651109
[TBL] [Abstract][Full Text] [Related]
2. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
Li M; Tang H; Chan MD; Zhou X; Qian X
Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
[TBL] [Abstract][Full Text] [Related]
3. Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment Against Glioblastoma.
Cuccarini V; Aquino D; Gioppo A; Anghileri E; Pellegatta S; Schettino C; Mazzi F; Finocchiaro G; Bruzzone MG; Eoli M
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31744235
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
6. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
[TBL] [Abstract][Full Text] [Related]
7. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
[TBL] [Abstract][Full Text] [Related]
8. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
[TBL] [Abstract][Full Text] [Related]
9. The Use of Treatment Response Assessment Maps in Discriminating Between Radiation Effect and Persistent Tumoral Lesion in Metastatic Brain Tumors Treated with Gamma Knife Radiosurgery.
Peker S; Samanci Y; Aygun MS; Yavuz F; Erden ME; Nokay AE; Atasoy Aİ; Bolukbasi Y
World Neurosurg; 2021 Feb; 146():e1134-e1146. PubMed ID: 33253956
[TBL] [Abstract][Full Text] [Related]
10. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
11. MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis.
Müller SJ; Khadhraoui E; Ganslandt O; Henkes H; Gihr GA
J Neurooncol; 2024 Feb; 166(3):513-521. PubMed ID: 38261142
[TBL] [Abstract][Full Text] [Related]
12. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
[TBL] [Abstract][Full Text] [Related]
14. Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China.
Wang Y; Zhang J; Li W; Jiang T; Qi S; Chen Z; Kang J; Huo L; Wang Y; Zhuge Q; Gao G; Wu Y; Feng H; Zhao G; Yang X; Zhao H; Wang Y; Yang H; Kang D; Su J; Li L; Jiang C; Li G; Qiu Y; Wang W; Wang H; Xu Z; Zhang L; Wang R
Future Oncol; 2021 Nov; 17(33):4571-4582. PubMed ID: 34519220
[TBL] [Abstract][Full Text] [Related]
15. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
[TBL] [Abstract][Full Text] [Related]
16. Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.
Zach L; Guez D; Last D; Daniels D; Grober Y; Nissim O; Hoffmann C; Nass D; Talianski A; Spiegelmann R; Tsarfaty G; Salomon S; Hadani M; Kanner A; Blumenthal DT; Bukstein F; Yalon M; Zauberman J; Roth J; Shoshan Y; Fridman E; Wygoda M; Limon D; Tzuk T; Cohen ZR; Mardor Y
Neuro Oncol; 2015 Mar; 17(3):457-65. PubMed ID: 25452395
[TBL] [Abstract][Full Text] [Related]
17. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Pinho MC; Polaskova P; Kalpathy-Cramer J; Jennings D; Emblem KE; Jain RK; Rosen BR; Wen PY; Sorensen AG; Batchelor TT; Gerstner ER
Oncologist; 2014 Jan; 19(1):75-81. PubMed ID: 24309981
[TBL] [Abstract][Full Text] [Related]
18. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol.
Topkan E; Kucuk A; Ozdemir Y; Mertsoylu H; Besen AA; Sezen D; Bolukbasi Y; Pehlivan B; Selek U
J Immunol Res; 2020; 2020():8628540. PubMed ID: 33274245
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
20. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM
J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
